Literature DB >> 16476709

Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions.

K M J Douglas1, E Ladoyanni, G J Treharne, E D Hale, N Erb, G D Kitas.   

Abstract

BACKGROUND: Cutaneous abnormalities are common in rheumatoid arthritis, but exact prevalence estimates are yet to be established. Some abnormalities may be independent and coincidental, whereas others may relate to rheumatoid arthritis or its treatment.
OBJECTIVES: To determine the exact nature and point prevalence of cutaneous abnormalities in patients with rheumatoid arthritis compared with those in patients with non-inflammatory rheumatic disease.
METHODS: 349 consecutive outpatients for rheumatology (205 with rheumatoid arthritis and 144 with non-inflammatory rheumatic conditions) were examined for skin and nail signs by a dermatologist. Histories of rheumatology, dermatology, drugs and allergy were noted in detail.
RESULTS: Skin abnormalities were reported by more patients with rheumatoid arthritis (61%) than non-inflammatory controls (47%). More patients with rheumatoid arthritis (39%) than controls (10%) attributed their skin abnormality to drugs. Cutaneous abnormalities observed by the dermatologist were also more common in patients with rheumatoid arthritis (76%) than in the group with non-inflammatory disease (60%). Specifically, bruising, athlete's foot, scars, rheumatoid nodules and vasculitic lesions were more common in patients with rheumatoid arthritis than in controls. The presence of bruising was predicted only by current steroid use. The presence of any other specific cutaneous abnormalities was not predicted by any of the variables assessed. In the whole group, current steroid use and having rheumatoid arthritis were the only important predictors of having any cutaneous abnormality.
CONCLUSIONS: Self-reported and observed cutaneous abnormalities are more common in patients with rheumatoid arthritis than in controls with non-inflammatory disease. These include cutaneous abnormalities related to side effects of drugs or to rheumatoid arthritis itself and other abnormalities previously believed to be independent but which may be of clinical importance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476709      PMCID: PMC1798318          DOI: 10.1136/ard.2005.048934

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  37 in total

1.  Meloxicam-induced erythema multiforme.

Authors:  S N Nikas; G Kittas; N Karamaounas; A A Drosos
Journal:  Am J Med       Date:  1999-11       Impact factor: 4.965

2.  Toxic epidermal necrolysis after celecoxib therapy.

Authors:  Peter Berger; Daniel Dwyer; Carmela E Corallo
Journal:  Pharmacotherapy       Date:  2002-09       Impact factor: 4.705

Review 3.  Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.

Authors:  F Soliotis; M Glover; A S M Jawad
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

4.  Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.

Authors:  Joel M Kremer; Mark C Genovese; Grant W Cannon; Jacques R Caldwell; John J Cush; Daniel E Furst; Michael E Luggen; Ed Keystone; Michael H Weisman; William M Bensen; Jeffrey L Kaine; Eric M Ruderman; Patricia Coleman; David L Curtis; Elliot J Kopp; Seth M Kantor; Jonathan Waltuck; Herbert B Lindsley; Joseph A Markenson; Vibeke Strand; Bruce Crawford; Indra Fernando; Karen Simpson; Joan M Bathon
Journal:  Ann Intern Med       Date:  2002-11-05       Impact factor: 25.391

5.  Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis.

Authors:  K-R Chen; A Toyohara; A Suzuki; S Miyakawa
Journal:  Br J Dermatol       Date:  2002-11       Impact factor: 9.302

6.  Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study.

Authors:  E J Kroot; A M van Gestel; H L Swinkels; M M Albers; L B van de Putte; P L van Riel
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

7.  Celecoxib-induced Sweet's syndrome.

Authors:  K H Fye; E Crowley; T G Berger; P E LeBoit; M K Connolly
Journal:  J Am Acad Dermatol       Date:  2001-08       Impact factor: 11.527

8.  The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients.

Authors:  C M Magro; A N Crowson
Journal:  J Cutan Pathol       Date:  2003-01       Impact factor: 1.587

9.  The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century.

Authors:  D Symmons; G Turner; R Webb; P Asten; E Barrett; M Lunt; D Scott; A Silman
Journal:  Rheumatology (Oxford)       Date:  2002-07       Impact factor: 7.580

10.  Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.

Authors:  P Tugwell; T Pincus; D Yocum; M Stein; O Gluck; G Kraag; R McKendry; J Tesser; P Baker; G Wells
Journal:  N Engl J Med       Date:  1995-07-20       Impact factor: 91.245

View more
  4 in total

Review 1.  Foot health in patients with rheumatoid arthritis-a scoping review.

Authors:  Minna Stolt; Riitta Suhonen; Helena Leino-Kilpi
Journal:  Rheumatol Int       Date:  2017-03-21       Impact factor: 2.631

Review 2.  Cutaneous manifestations associated with rheumatoid arthritis.

Authors:  T Yamamoto
Journal:  Rheumatol Int       Date:  2009-02-26       Impact factor: 2.631

3.  Mucocutaneous Manifestations in Patients with Rheumatoid Arthritis: A Cross-sectional Study from Eastern India.

Authors:  Sudip Kumar Ghosh; Debabrata Bandyopadhyay; Surajit Kumar Biswas; Ivoreen Darung
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

4.  Reporting of Research Ethics in Studies Focusing on Foot Health in Patients with Rheumatoid Arthritis - A Systematic Review.

Authors:  Minna Stolt; Emilia Kielo-Viljamaa; Anne-Marie Laitinen; Riitta Suhonen; Helena Leino-Kilpi
Journal:  J Empir Res Hum Res Ethics       Date:  2021-10-14       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.